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in Pakistan
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Sehrish Muneer1, Sana Muslim1, Aneeta Hotwani1, Furqan Kabir1, Cynthia Whitney2, Lindsay Kim2,
Velusamy Srinivasan2, Asad Ali1, Anita K. M. Zaidi1,3 and Fyezah Jehan1*

Abstract
Background: Benefits of pneumococcal conjugate vaccine programs have been linked to the vaccine’s ability to
disrupt nasopharyngeal carriage and transmission. The 10-valent pneumococcal vaccine (PCV10) was included in
the Expanded Program on Immunization (EPI) in Sindh, Pakistan in February 2013. This study was carried out
immediately before PCV10 introduction to establish baseline pneumococcal carriage and prevalent serotypes
in young children and to determine if carriage differed in urban and rural communities.
Methods: Nasopharyngeal specimens were collected from a random sample of children 3-11 and 12-59 months of
age in an urban community (Karachi) and children 3-11 months of age in a rural community (Matiari). Samples were
processed in a research laboratory in Karachi. Samples were transported in STGG media, enriched in Todd Hewitt broth,
rabbit serum and yeast extract, cultured on 5% sheep blood agar, and serotyped using the CDC standardized
sequential multiplex PCR assay. Serotypes were categorized into PCV10-type and non-vaccine types.
Results: We enrolled 670 children. Pneumococci were detected in 73.6% and 79.5 % of children in the infant
group in Karachi and Matiari, respectively, and 78.2% of children 12 to 59 months of age in Karachi. In infants, 38.
9% and 33.5% of those carrying pneumococci in Karachi and Matiari, respectively, had PCV10 types. In the older age
group in Karachi, the proportion was 30.7%, not significantly different from infants. The most common serotypes were
6A, 23F, 19A, 6B and 19F.
Conclusion: We found that about 3 of 4 children carried pneumococci, and this figure did not vary with age group or
urban or rural residence. Planned annual surveys in the same communities will inform change in carriage of PCV10
serotype pneumococci after the introduction and uptake of PCV10 in these communities
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Background
The World Health Organization estimates that pneumococcal infections kill around 541,000 children under the
age of 5 years globally every year, with pneumococcal
pneumonia responsible for 485,000 deaths [1].
The upper respiratory tract is the ecological niche for
the pneumococcus and colonization is established during the first months of life [2]. Colonization is generally
asymptomatic, but in some it may progress to invasive
pneumococcal disease (IPD) or non-invasive disease [3].
Fortunately, both colonization and disease due to
Streptococcus pneumoniae can be prevented by administration of pneumococcal conjugate vaccine (PCV).
Studies done in the US, Africa and Europe have shown
that PCV introduction caused a decrease in invasive
pneumococcal disease and other pneumococcal syndromes [2, 4–8]. Reports also illustrated that PCV use
decreased nasopharyngeal carriage of vaccine serotypes
of Streptococcus pneumoniae [9–12].The initial vaccine
introduced in the immunization programs of most countries in the mid-2000’s was the 7-valent vaccine, which
was replaced by the 10- (PCV10) or 13-valent vaccine
(PCV13) at the end of the decade [2, 5].
Introduction of PCV10 into routine immunization
began in Sindh, Pakistan in February 2013 with financing assistance from the GAVI Alliance. The vaccine
was introduced with a 3+0 schedule, with doses given
at 6, 10 and 14 weeks of life. No catch-up vaccination
was offered.
The prevalence of pneumococcal carriage can be used
to estimate the potential for PCVs to reduce transmission of vaccine-type strains [13] and indirectly translates
into impact on disease, as shown by previous carriage
studies [11, 14, 15]. Such knowledge of baseline serotype
prevalence among carriage strains in young children is
important for countries like Pakistan, where the vaccine
coverage is low and incidence of invasive pneumococcal
disease (IPD) is quite high [16, 17]. There could be possible differences between carriage rates in the urban and
rural populations due to difference in accessibility to
care, socio-economic conditions and public health
awareness. It would be beneficial to study both populations separately, in order to come up with more effective
health policies for each sector.
We undertook this study to determine baseline carriage rates in children 3 to 11 months of age in
urban and rural communities and 1-5 years old in the
urban community of Sindh, Pakistan, before introduction of PCV10.
Methods
Study design and setting

This was a cross-sectional survey done in two union
councils of rural Matiari and one union council of urban
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Karachi, both in the southern province of Sindh, Pakistan.
These sites were selected because of pre-existing infrastructure and ongoing research in the community. A
union council is the smallest administrative unit in the
government structure. Matiari is around 180 km away
from Aga Khan University (AKU) in Karachi, which
houses the research unit and the Infectious Disease
Research Laboratory (IDRL). The field site in urban
Karachi was located around 20 km from AKU. This
survey was done during the months of January and
February 2013, immediately before the introduction of
PCV10 vaccine in Sindh.
All children aged 3 to 11 months resident in the study
area in the Matiari site and all children under the age of
5 years in the Karachi site were eligible to be enrolled in
the study. A random sample of children 3 to 11 months
of age was selected from a household listing of two
union councils, Khyber and Seekhat, in Matiari. In Karachi
an additional random sample of children 12 to 59 months
was selected from a line listing of all children living in the
area. Children with a history of severe acute respiratory illness in the last 2 weeks, presence of chest wall
indrawing, blue skin discoloration (cyanosis) and fast
breathing were excluded from the study. Children
with moderate to severe cerebral palsy, neurological
disorders affecting swallowing and nose and throat
disorders were also excluded. If a child was not found, or
found to be ineligible in the random list, the next eligible
child in the list was approached.
Baseline demographic data and clinical characteristics
of children were collected through a questionnaire
(available as a supplementary file). The questionnaire
was developed, translated and back-translated between
English, Urdu and Sindhi languages and pretested in the
field before implementation. A two-day training was
held for staff involved in the study to standardize data
and specimen collection methods. Crowding index
was developed by dividing number of people by number of rooms in the household, axillary temperature
was measured using a digital thermometer and vaccination history was collected either verbally or verified through card.
Laboratory methods

Nasopharyngeal swabs were collected by trained staff as
per World Health Organization methods [18]. Swabs
were immediately placed into skim milk tryptone glucose glycerol (STGG) media in cryovials and transported
to the Infectious Disease Research Laboratory (IDRL) in
Karachi at 2-8°C within 6-8 hours of collection. Upon
reaching the central laboratory, inoculated STGG was
vortexed for 10-20 seconds to disperse organisms from
the swab and frozen in an upright position at -70°C until
further processing. Samples were then cultured in batches
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of 20-40 samples and sub-cultured as described in the
CDC protocol (https://www.cdc.gov/streplab/downloads/
pcr-pneumo-carriage-march2010.pdf). Briefly, an aliquot
of the thawed STGG mixture was enriched in Todd
Hewitt broth supplemented with rabbit serum (20%) and
yeast extract (0.5%) and subcultured onto TSA medium
with 5% sheep blood. After 18-24 hours of incubation,
plates were examined for the presence of alpha-haemolytic
colonies with morphological characteristic features of
pneumococci. There was only one case where two colonies were identified and the dominant one was elected.
Identification was confirmed by susceptibility to Optochin
and bile solubility testing.
Serotypes for the pneumococcal isolates were deduced
by sequential conventional multiplex PCR method as described in CDC Streptococcus laboratory protocols [19].
Briefly, DNA was extracted by boiling a loop full of bacterial culture in 1 ml of TE Buffer at 100 °C for 10 minutes followed by centrifugation at 10,000 rpm for 10
minutes; the resulting supernatant was collected in a
new sterile 1.5 ml microfuge tube and 2 μl of the extracted DNA was directly used in the PCR reaction. The
cpsA gene was included in each multiplex reaction to
serve as an internal positive control. PCR master mix (of
23 μl) was prepared using 25 μM working stock of
primers, 2X Qiagen multiplex PCR buffer, Qiagen Q solution and nuclease free water, with 2 μl of DNA template added to the reaction mixture. Amplification was
carried out in an Eppendorf Master Cycler Gradient with
the following temperature profile: initial denaturation at
95 °C for 15 minutes, then 35 cycles consisting of 94 °C
for 30 seconds, 54 °C for 90 seconds, and 72 °C for 60
seconds, followed by a final extension step at 72 °C for
10 minutes. The amplified PCR products were separated
on 2% (w/v) agarose gel electrophoresis, stained with 1X
SYBR-green staining solution, and documented under
BioRad Gel Doc imager. Serotypes detected through
sequential multiplex conventional PCR were further confirmed by monoplex PCR, using the same PCR conditions,
to avoid misidentification due to non-specific bands [20].
Serogroup 6 was further discriminated into individual
serotypes, 6A, 6B, 6C, and 6D by conventional PCR as
described by Jin et al. [19, 20] with slight modifications,
using 25 μM working stocks of primers, 2X Qiagen
multiplex PCR buffer, Qiagen Q solution and nuclease
free water, with 2 μl of DNA template added to the reaction mixture. Amplification reactions were conducted
using a Eppendorf Master Cycler Gradient with the following temperature profile: initial denaturation at 95°C
for 15 minutes, then 35 cycles consisting of 94°C for 30
seconds, 66.2°C for 60 seconds, and 72°C for 60 seconds,
followed by a final extension step at 72°C for 10 minutes.
Appropriate pneumococcal serotype controls obtained
from the CDC streptococcal lab were included in every
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reaction. The amplified PCR products were separated on
2.5% (w/v) agarose gel electrophoresis, stained with 1X
SYBR -green staining solution, and documented under a
Biorad Gel Doc imager.
Identification of non-typeable pneumococcal isolates
(those with no positive results for any tested serogroups/
types) was confirmed with a lytA real time PCR as described by Carvalho et al. [21].
For Optochin susceptibility and bile solubility reactions, the following reference American Type Culture
Collection (ATCC) strains were used for quality control:
Streptococcus pneumoniae ATCC 49619 and Enterococcus
faecalis ATCC 29212. In addition, a total of 176 randomly
selected pneumococcal isolates were sent to CDC to cross
check PCR serotying results with the Quellung reaction;
95% concordance was found between PCR and CDC
Quellung reaction results.
Sample size calculations

Sample size was calculated based on a predictive decline
in NP carriage in subsequent years after the introduction
of vaccine. There are no recent data regarding prevalence of pneumococcal carriage in Pakistan. One study
from 1993 reported prevalence of PCV7 serotypes in
children 2-24 months as 50% and 65 % [22]. To obtain
maximum sample size, a baseline carriage rate of 50%
was assumed. This gave a sample size of 220 in order to
show a decrease in prevalence from 0.5 to 0.3 after
introduction of PCV10 with 80% power and 5 % level of
significance.
Data management and quality assurance

Data consisting of demographic and socio-economic indicators as well as general health status and common
symptoms were collected on paper forms by trained
personnel at the designated fieldwork sites. All participants were assigned a unique identifier and a linking
identification number from the demographic surveillance system was also noted. All completed forms were
reviewed by the study supervisor at the end of the day
for completeness and consistency. Data were dual entered in an MS Access database and validation and
consistency checks were run. Analysis was done using
STATA version 12 and MS EXCEL. Confidence bound
for predictors such as age, gender, educational status etc.
were created using a logistic regression model. All variables that were found to be significant at a p-value of ≤
0.10 at univariate level were added in a multivariate
model. A stepwise backward elimination approach was
used to derive a parsimonious model retaining only variables with a P-value of <0.05. Odds ratios with 95% confidence intervals were calculated. Analysis was done
looking at overall nasopharyngeal carriage as well as
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Table 1 Socio demographic and clinical characteristics of
enrolled children
Variable

Karachi
(3 -11 months)
N = 220

Karachi
(12-59 months)
N = 225

Matiari
(3 -11 months)
N = 225

N (%)

N (%)

N (%)

Age, mean (SD)

9.8 (6.1)

39.6 (12.7)

6.5 (2.6)

Male gender

102 (46.4)

107 (47.6)

125 (55.6)

Primary caretaker education
Illiterate

92 (41.9)

103 (45.8)

144 (64.0)

1-5 years

25 (11.4)

19 (8.4)

31 (13.8)

6-10 years

47 (21.4)

43 (19.1)

16 (7.1)

>10 years

56 (25.5)

60 (26.7)

34 (15.1)

Crowding index (persons/room)
Mean (SD)

4.4 (2.0)

4.4 (2.1)

5.8 (2.5)

Hospitalization
in last year

15 (6.8)

0 (0.0)

8 (3.6)

No. of outpatient visits in last month
Mean (SD)

1.8 (1.0)

1.7 (0.9)

2.0 (2.5)

Fever (current or
in last 3 days)

30 (13.6)

20 (8.9)

4 (1.8)

Cough

64 (29.1)

51 (22.7)

41 (18.2)

220 (97.8)

28 (12.4)

Type of Fuel used in cooking
Natural gas

216 (98.2)

Other

4 (1.8)

5 (2.2)

197 (87.6)

Child exposed to
smoke during
cooking

0 (0.0)

1 (0.4)

150 (66.7)

Smoker in the
Household

48 (21.8)

45 (20.0)

110 (48.9)

Ever vaccinateda

170 (77.3)

170 (75.6)

157 (69.8)

SD Standard Deviation ahaving received any vaccine

carriage of PCV10 specific serotypes as the outcome
and 95% confidence intervals were presented.
Ethical approval

Ethical approval was obtained from Aga Khan University’s
Ethical Review Committee. The study was performed
according to approved protocol.

Results
A total of 220 and 225 children aged 3 to 11 months
old were enrolled in Karachi and Matiari, respectively.

An additional 225 children aged 12 to 59 months were enrolled in Karachi. Table 1 gives the demographic and clinical characteristics of all enrolled children.
It was noted that the literacy rate among the primary caretakers in the Matiari site was lower than
that in Karachi, and the household crowding index
was higher. A huge majority of children living in
Matiari were exposed to smoke, through cooking fuel
as well as passive tobacco smoking. Immunization rates
were low in both sites.
Overall carriage did not differ significantly by age or
between the urban and rural sites (Table 2).
In the infant group, 73.6% (95% CI, 67.3-79.3) and
79.5% (95% CI, 73.7-84.6) of the nasopharyngeal specimens were positive for pneumococci in Karachi and
Matiari, respectively. In the older age group in Karachi,
78.2% (95% CI, 72.2-83.4) of specimens were positive for
pneumococci. Among the isolates, the proportion that
was PCV10 serotypes was 38.9% (95% CI, 31.3-46.8) and
33.5% (95% CI, 26.6-41.0) in 3 to 11 months-old children in Karachi and Matiari, respectively, and 30.7%
(95% CI, 24.0-38.0) in children 12-59 months of age
in Karachi (Table 2).
There was no statistically significant difference in carriage between urban and rural populations in the infant
group or in the two age groups in the urban population,
for both vaccine and non-vaccine types. Taking all sampled children as the denominator, the carriage rate for
PCV10 serotypes was 26.7% and 28.6% for children 3-11
months in Matiari and Karachi, respectively, and 24% in
children 12-59 months in Karachi. Preliminary results
have been previously presented as an abstract [23].
Figure 1 gives the serotype distribution of the specimens that were culture positive in Karachi and Matiari.
The most frequent PCV10 serotypes in Karachi 3-11
month-olds were 6B, 19F and 23F, while in Matiari 23F,
9V and 14 were most common. In the older age group
in Karachi, the most common serotypes were 6B, 18C
and 19F. Carriage rates for PCV13-specific serotypes
were significantly higher than PCV10 serotype carriage
in Matiari (53.1% vs. 33.5%, p-value<0.001), Karachi 3-11
month-olds (54.3% vs. 38.9%, p-value=0.005) and Karachi
children 12-59 months (44.3% vs. 30.7%, p-value=0.008;
Table 2). The carriage rate for PCV10 as well as 6A was
44.1% in Matiari 3-11 months, 48.1% in Karachi 3-11
months and 38.1% in Karachi 12-59 months. None of the

Table 2 Number and proportion of children carrying pneumococcus and vaccine serotypes by age and study site
Study Site

Number of participants (n)

Number culture-positive
for pneumococcus (%)

Number with PCV10
serotypes (% of isolates)

Number with PCV13
serotypes (% of isolates)

Matiari (3-11 months)

225

179 (79.5)

60 (33.5)

95 (53.1)

Karachi (3-11 months)

220

162 (73.6)

63 (38.9)

88 (54.3)

Karachi (12-59 months)

225

176 (78.2)

54 (30.7)

78 (44.3)
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C

Fig. 1 Number of serotypes by study site and age group; a) Matiari (rural site) children 3-11 months of age; b) Karachi (urban site) children 3-11
months of age; and c) Karachi (urban site) children 12-59 months of age
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socio-demographic or clinical features we measured were
associated with pneumococcal carriage overall or with carriage of PCV10 serotypes (Additional file 1: Table S1)

Discussion
This study has revealed high point prevalence of
pneumococcal carriage in the nasopharynx among children in lower Sindh. These rates are higher than those
observed in other countries in the region [21]. Carriage
rates were closer to those reported in many African
countries and rural areas in other parts of the world
[24–26]. Pneumococcal carriage in the urban area was
as high as in the rural setting. This is in contrast to
other studies which have shown the carriage in urban
areas to be lower [27, 28]. Our results further reveal that
there is no variation in the carriage rates or carriage of
vaccine serotypes across the two age groups we examined, in spite of notable differences in smoke exposure
and markers of economic status such as maternal education level between urban and rural areas.
Our results have shown a significant burden of
PCV13-specific serotypes among children in Pakistan.
Although it has been proposed that PCV10 confers
cross-protection against some PCV13 specific serotypes
such as 6A and 19A, the evidence regarding this is inconclusive [29, 30]. Disease surveillance data will be
needed to understand if the additional serotypes covered by PCV13 cause enough burden to warrant a
change in the pneumococcal vaccine used in Pakistan’s
immunization program. This study indicates that there is
a large reservoir of pneumococci in the nasopharynx in infants, implying an effective role for this vaccine in this age
group in both urban and rural areas. Thus it will be important to see the impact of the vaccine on carriage rates
with the current EPI program, especially because coverage
rates for routine infant immunizations are low in some
areas of Pakistan [17]. While older children may be less
susceptible to disease than infants, our data showing high
carriage rates suggests these older children may be functioning as direct reservoirs for transmitting pneumococci to each other, to adults, and to the more
susceptible infants.
An important strength of the study is that it was done
immediately before the introduction of PCV10 in
Pakistan. None of the children in the study area had received a pneumococcal vaccine. We intend to repeat
similar cross sectional surveys in subsequent years after
the introduction of vaccine to gauge the effect of the
PCV10 vaccine in decreasing carriage of vaccine type
strains and whether particular non-vaccine serotype
pneumococci become more prevalent. We also wish to
study whether the change in carriage led to a change in
the prevalence of IPD and the burden of pneumonia.
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There are some limitations to the study. The study
areas were limited to an urban and rural population in
the southern province of Pakistan, and whether carriage
or serotype distribution is different in other parts of
Pakistan is unknown. Although we tried to ensure quality control by sharing a subset of isolates with CDC and
comparing with Quellung method, PCR is still not as
sensitive and we may have underestimated carriage [31].
Another limitation might be that we did not evaluate
carriage density among carriers of pneumococci, because
we opted to use culture methods that included an enrichment step designed to optimize recovery of pneumococci; therefore, we were not able to examine the
association between carriage density and variables such
as fever, hospitalization, and exposure to smoke. We
were also unable to identify known risk factors associated with carriage such as breastfeeding and prior antibiotic use because this information was not collected.
This may explain why we found no risk factors.
Since carriage density varies with age, the results
might have been significantly different across age groups
[32]. Since we studied the prevalence of vaccine and
non-vaccine serotypes, the main crux of this study is
therefore to inform serotype distribution among carriage
pneumococci in a vaccine-naïve pediatric population,
and serve as a baseline for assessing impact of PCV10
introduction on carriage rates among vaccinees as well
as non-vaccinated older children (indirect effect).

Conclusion
This survey establishes the pre PCV10 introduction vaccine and non-vaccine serotype carriage rate in children
in a rural and urban community in Pakistan. In spite of
differences in the social situation of children enrolled
from these two communities, carriage overall and of vaccine serotypes was equally high in both settings, suggesting potential benefits from PCV introduction regardless
of setting. Annually planned surveys in the same communities will inform change in carriage rate after the
introduction and uptake of PCV10 in these communities. Linkage with data showing impact on disease endpoints will allow for a full picture of the impact of
PCV10 in Pakistan.
Additional file
Additional file 1: Table S1. Association of different variables with
pneumococcal carriage. (DOC 47 kb)
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